Nifty
:
24834.85
Sensex
:
81332.72
428.75 (1.76%)
1292.92 (1.62%)
Nifty
Sensex
:
:
24834.85
81332.72
428.75 (1.76%)
1292.92 (1.62%)

Jubilant Pharmova Ltd.

Chemicals

Rating :
55/99

BSE: 530019 | NSE: JUBLPHARMA

NSE BSE
751.40
05-Jul-2024
  • Open
  • High
  • Low
  • Previous Close
  •  747.95
  •  780.30
  •  746.50
  •  749.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  381682
  •  2913.86
  •  800.00
  •  318.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,495.32
  • 20.79
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 13,952.62
  • 0.69%
  • 1.94

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.68%
  • 4.09%
  • 17.78%
  • FII
  • DII
  • Others
  • 19.5%
  • 2.25%
  • 5.70%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.80
  • -7.17
  • 0.99

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -2.70
  • -14.90
  • -11.08

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 50.80
  • -19.51
  • -38.50

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.14
  • 14.05
  • 13.08

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.06
  • 1.59
  • 1.42

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 9.17
  • 8.69
  • 9.45

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Net Sales
1,731.70
1,586.90
9.12%
1,758.60
1,678.00
4.80%
1,677.10
1,552.50
8.03%
1,680.30
1,599.50
5.05%
Expenses
1,480.20
1,417.30
4.44%
1,487.20
1,458.80
1.95%
1,459.10
1,406.60
3.73%
1,438.50
1,380.80
4.18%
EBITDA
251.50
169.60
48.29%
271.40
219.20
23.81%
218.00
145.90
49.42%
241.80
218.70
10.56%
EBIDTM
14.52%
10.69%
15.43%
13.06%
13.00%
9.40%
14.39%
13.67%
Other Income
14.00
8.60
62.79%
14.40
4.40
227.27%
35.80
9.50
276.84%
9.90
13.10
-24.43%
Interest
71.00
61.90
14.70%
73.00
55.60
31.29%
71.30
50.70
40.63%
66.10
42.00
57.38%
Depreciation
90.70
89.70
1.11%
101.00
271.20
-62.76%
94.60
94.30
0.32%
96.60
93.90
2.88%
PBT
499.70
26.60
1,778.57%
-57.10
-103.20
-
87.90
10.40
745.19%
89.00
39.10
127.62%
Tax
17.90
19.20
-6.77%
8.10
14.10
-42.55%
34.60
24.80
39.52%
35.90
31.50
13.97%
PAT
481.80
7.40
6,410.81%
-65.20
-117.30
-
53.30
-14.40
-
53.10
7.60
598.68%
PATM
27.82%
0.47%
-3.71%
-6.99%
3.18%
-0.93%
3.16%
0.48%
EPS
30.51
0.41
7,341.46%
-3.71
-6.16
-
4.23
-0.98
-
3.96
0.34
1,064.71%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
6,847.70
6,281.73
6,130.16
6,098.53
9,154.41
9,110.82
7,517.84
5,861.43
5,749.13
5,826.25
5,803.36
Net Sales Growth
6.71%
2.47%
0.52%
-33.38%
0.48%
21.19%
28.26%
1.95%
-1.32%
0.39%
 
Cost Of Goods Sold
2,182.30
1,877.94
1,488.01
1,536.01
3,140.58
3,521.84
2,862.51
2,002.74
2,116.20
2,663.02
2,438.46
Gross Profit
4,665.40
4,403.79
4,642.16
4,562.52
6,013.84
5,588.98
4,655.33
3,858.69
3,632.94
3,163.23
3,364.90
GP Margin
68.13%
70.10%
75.73%
74.81%
65.69%
61.34%
61.92%
65.83%
63.19%
54.29%
57.98%
Total Expenditure
5,865.00
5,505.49
4,973.83
4,702.07
7,207.34
7,371.81
5,999.45
4,516.14
4,502.19
5,124.71
4,782.37
Power & Fuel Cost
-
166.71
134.30
105.79
112.21
466.38
424.91
333.66
366.71
393.04
389.74
% Of Sales
-
2.65%
2.19%
1.73%
1.23%
5.12%
5.65%
5.69%
6.38%
6.75%
6.72%
Employee Cost
-
2,166.02
2,043.39
1,922.88
2,127.68
1,925.96
1,555.88
1,230.93
1,125.09
1,090.28
1,105.17
% Of Sales
-
34.48%
33.33%
31.53%
23.24%
21.14%
20.70%
21.00%
19.57%
18.71%
19.04%
Manufacturing Exp.
-
581.13
562.32
449.40
362.15
552.26
485.98
428.84
436.46
432.40
405.14
% Of Sales
-
9.25%
9.17%
7.37%
3.96%
6.06%
6.46%
7.32%
7.59%
7.42%
6.98%
General & Admin Exp.
-
464.06
432.34
387.92
416.80
540.75
354.56
280.98
256.23
302.28
264.23
% Of Sales
-
7.39%
7.05%
6.36%
4.55%
5.94%
4.72%
4.79%
4.46%
5.19%
4.55%
Selling & Distn. Exp.
-
161.60
209.71
177.15
194.71
267.70
247.85
185.79
135.54
203.98
160.04
% Of Sales
-
2.57%
3.42%
2.90%
2.13%
2.94%
3.30%
3.17%
2.36%
3.50%
2.76%
Miscellaneous Exp.
-
88.03
103.77
122.93
853.22
96.92
67.76
53.20
65.96
39.72
160.04
% Of Sales
-
1.40%
1.69%
2.02%
9.32%
1.06%
0.90%
0.91%
1.15%
0.68%
0.34%
EBITDA
982.70
776.24
1,156.33
1,396.46
1,947.07
1,739.01
1,518.39
1,345.29
1,246.94
701.54
1,020.99
EBITDA Margin
14.35%
12.36%
18.86%
22.90%
21.27%
19.09%
20.20%
22.95%
21.69%
12.04%
17.59%
Other Income
74.10
38.33
11.29
17.64
47.43
35.74
40.03
24.86
13.37
42.45
19.06
Interest
281.40
188.20
145.49
184.10
287.41
219.81
284.28
341.11
371.35
367.61
337.11
Depreciation
382.90
554.03
381.70
348.95
461.93
370.90
415.05
291.40
346.74
287.95
281.17
PBT
619.50
72.34
640.43
881.05
1,245.17
1,184.04
859.08
737.64
542.22
88.43
421.78
Tax
96.50
92.66
217.43
297.22
312.29
326.80
224.66
163.02
155.40
80.48
69.64
Tax Rate
15.58%
597.04%
33.95%
34.57%
25.80%
36.16%
26.15%
22.10%
28.66%
199.55%
33.60%
PAT
523.00
-60.98
413.94
562.87
898.24
574.46
642.81
575.66
391.83
-57.76
109.04
PAT before Minority Interest
527.30
-64.88
413.02
562.61
898.24
577.01
634.42
574.63
386.82
-40.16
137.64
Minority Interest
4.30
3.90
0.92
0.26
0.00
-2.55
8.39
1.03
5.01
-17.60
-28.60
PAT Margin
7.64%
-0.97%
6.75%
9.23%
9.81%
6.31%
8.55%
9.82%
6.82%
-0.99%
1.88%
PAT Growth
548.16%
-
-26.46%
-37.34%
56.36%
-10.63%
11.66%
46.92%
-
-
 
EPS
32.83
-3.83
25.98
35.33
56.39
36.06
40.35
36.14
24.60
-3.63
6.84

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
5,399.28
5,318.56
4,741.49
5,603.88
4,808.92
4,086.53
3,436.04
2,966.26
2,453.52
2,626.51
Share Capital
15.91
15.92
15.92
15.93
15.93
15.58
15.57
15.54
15.93
15.45
Total Reserves
5,377.18
5,298.98
4,724.75
5,587.95
4,792.94
4,070.78
3,419.98
2,950.72
2,437.59
2,611.07
Non-Current Liabilities
3,765.02
2,921.59
2,973.05
4,087.52
4,420.21
3,417.47
3,826.06
3,347.13
4,036.15
2,184.95
Secured Loans
265.05
200.94
20.78
728.92
811.65
729.88
1,581.96
2,620.41
3,316.29
1,716.67
Unsecured Loans
2,845.32
2,263.30
2,543.19
3,010.76
3,431.24
2,317.93
1,923.07
392.79
375.00
0.22
Long Term Provisions
92.25
95.67
94.01
150.75
114.35
107.08
80.69
70.31
67.04
219.53
Current Liabilities
1,772.40
1,591.60
1,048.83
2,619.01
2,089.73
2,004.69
1,684.04
2,464.44
2,129.16
3,894.41
Trade Payables
821.32
567.74
520.48
1,090.27
1,020.13
1,136.16
749.49
612.12
721.19
718.14
Other Current Liabilities
552.10
838.52
371.73
674.21
473.57
505.87
572.70
951.43
793.31
1,731.20
Short Term Borrowings
258.25
64.00
20.00
649.89
499.71
244.85
255.60
748.97
517.17
1,187.83
Short Term Provisions
140.73
121.34
136.62
204.64
96.31
117.81
106.24
151.93
97.49
257.25
Total Liabilities
10,929.21
9,829.59
8,763.40
12,310.41
11,318.96
9,457.17
8,898.75
8,739.70
8,618.83
8,863.81
Net Block
5,183.26
4,870.61
4,608.75
6,339.97
5,648.38
5,400.55
5,106.73
5,104.42
4,911.33
5,098.78
Gross Block
7,431.77
6,758.89
6,089.57
7,982.83
6,905.50
6,288.86
5,672.38
5,390.82
7,362.10
7,330.63
Accumulated Depreciation
2,248.51
1,888.28
1,480.83
1,642.85
1,257.12
888.31
565.66
286.40
2,450.76
2,231.85
Non Current Assets
7,166.81
6,320.40
5,810.90
7,272.06
6,734.16
6,267.41
5,950.63
5,864.37
5,904.29
5,935.78
Capital Work in Progress
1,561.48
1,089.57
896.99
768.39
901.43
670.97
683.78
611.32
596.60
472.39
Non Current Investment
256.42
238.60
240.96
69.36
115.11
123.52
102.71
85.43
39.50
33.99
Long Term Loans & Adv.
161.55
117.64
62.84
86.81
68.59
71.79
56.32
62.67
327.17
328.42
Other Non Current Assets
4.09
3.98
1.35
7.53
0.66
0.58
1.08
0.53
29.68
2.21
Current Assets
3,762.40
3,509.19
2,952.50
5,038.35
4,584.80
3,189.76
2,948.12
2,875.32
2,714.54
2,928.03
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Inventories
1,380.53
1,254.87
1,129.38
1,845.38
1,417.39
1,391.39
1,220.40
1,203.10
1,235.33
1,341.42
Sundry Debtors
961.24
927.99
819.90
1,293.22
1,271.55
1,130.76
1,005.30
950.50
819.27
805.87
Cash & Bank
1,014.30
984.24
671.32
1,399.87
1,370.41
248.79
459.63
344.58
394.34
479.53
Other Current Assets
406.33
110.93
242.37
419.59
525.44
418.81
262.79
377.13
265.59
301.21
Short Term Loans & Adv.
271.28
231.17
89.53
80.29
39.80
45.75
37.06
133.06
144.56
136.04
Net Current Assets
1,990.00
1,917.59
1,903.67
2,419.34
2,495.07
1,185.06
1,264.08
410.88
585.38
-966.38
Total Assets
10,929.21
9,829.59
8,763.40
12,310.41
11,318.96
9,457.17
8,898.75
8,739.69
8,618.83
8,863.81

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
660.67
837.54
1,784.27
1,542.94
1,121.51
1,303.20
1,268.49
1,098.89
783.26
772.27
PBT
27.78
630.45
1,212.01
1,210.53
903.81
859.08
737.64
542.22
40.32
207.28
Adjustment
782.88
579.47
716.48
760.74
861.53
687.81
637.90
737.89
725.84
756.60
Changes in Working Capital
54.31
-178.29
249.90
-179.67
-300.53
14.15
36.88
-133.16
96.40
-110.70
Cash after chg. in Working capital
864.97
1,031.63
2,178.39
1,791.60
1,464.82
1,561.04
1,412.42
1,146.96
862.57
853.18
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-204.30
-194.09
-394.12
-248.66
-343.31
-257.84
-143.94
-48.07
-79.31
-80.91
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-544.41
-380.37
-739.01
-327.00
-1,011.84
-617.70
-450.39
-312.53
-343.33
-174.42
Net Fixed Assets
-100.77
-752.97
2,198.22
-241.66
-305.67
-147.58
-115.33
785.60
1,162.43
-166.96
Net Investments
-10.82
0.23
118.05
-0.14
-57.59
3.34
-0.39
57.01
239.81
-27.56
Others
-432.82
372.37
-3,055.28
-85.20
-648.58
-473.46
-334.67
-1,155.14
-1,745.57
20.10
Cash from Financing Activity
-156.68
-32.60
-1,709.39
-1,050.37
657.43
-901.13
-685.87
-842.75
-502.69
-414.41
Net Cash Inflow / Outflow
-40.43
424.57
-664.13
165.56
767.10
-215.63
132.22
-56.38
-62.76
183.44
Opening Cash & Equivalents
983.82
501.96
1,230.81
1,005.40
244.18
456.44
339.27
391.64
473.49
279.65
Closing Cash & Equivalent
1,013.92
983.82
501.96
1,230.81
1,005.40
244.18
456.44
339.27
391.63
473.49

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
339.04
333.91
297.84
351.83
301.93
262.33
220.61
190.90
154.04
170.07
ROA
-0.63%
4.44%
5.34%
7.60%
5.55%
6.91%
6.52%
4.46%
-0.46%
1.60%
ROE
-1.21%
8.21%
10.88%
17.25%
12.97%
16.87%
17.95%
14.27%
-1.58%
5.39%
ROCE
2.53%
9.97%
11.89%
15.07%
13.06%
15.21%
14.44%
12.42%
5.72%
7.92%
Fixed Asset Turnover
0.89
0.95
0.87
1.23
1.38
1.26
1.09
0.92
0.81
0.84
Receivable days
54.89
52.04
63.24
51.13
48.12
51.58
59.43
54.81
49.56
46.53
Inventory Days
76.57
70.98
89.02
65.05
56.26
63.07
73.64
75.51
78.58
75.51
Payable days
134.99
133.47
191.38
58.75
55.42
56.86
54.84
53.44
52.17
51.42
Cash Conversion Cycle
-3.54
-10.45
-39.12
57.43
48.96
57.79
78.23
76.88
75.98
70.61
Total Debt/Equity
0.63
0.55
0.55
0.83
1.01
0.85
1.18
1.51
1.95
1.67
Interest Cover
1.15
5.33
5.67
5.21
5.11
4.02
3.16
2.46
1.11
1.61

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Jubilant Pharmova reports many fold jump in Q1 consolidated net profit
    19th Jul 2024, 16:25 PM

    Total consolidated income of the company increased by 9.41% at Rs 1745.70 crore for Q1FY25

    Read More
  • USFDA concludes audit at contract manufacturing facility of Jubilant Pharmova’s step down arm
    18th Jun 2024, 17:43 PM

    The USFDA has issued 15 observations pursuant to the completion of audit

    Read More
  • USFDA concludes audit at Washington manufacturing facility of Jubilant Pharmova’s arm
    10th Jun 2024, 11:53 AM

    The USFDA has issued 3 observations pursuant to the completion of audit

    Read More
  • Jubilant Pharmova acquires 19.89% stake in O2 Renewable Energy XVI
    7th Jun 2024, 12:29 PM

    On March 29, 2024, the company had acquired 64,517 CCDs and 7,16,857 equity shares in O2

    Read More
  • Jubilant Pharmova - Quarterly Results
    29th May 2024, 14:56 PM

    Read More
  • Jubilant Pharmova’s arm approves proposal for investment in Isharays Energy
    29th May 2024, 10:42 AM

    The company has embarked on a renewable energy implementation journey across its facilities in India to enable reduction in both, cost and carbon footprint

    Read More
  • USFDA concludes audit at Radiopharmaceutical manufacturing facility of Jubilant Pharmova’s arm
    25th Apr 2024, 10:14 AM

    The USFDA has issued 5 observations pursuant to the completion of audit

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.